APA

Haddox C. L., Mangaonkar A. A., Chen D., Shi M., He R., Oliveira J. L., Litzow M. R., Al-Kali A., Hogan W. J. & Elliott M. A. (20180829). Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis. : Blood cancer journal.

Chicago

Haddox C L, Mangaonkar A A, Chen D, Shi M, He R, Oliveira J L, Litzow M R, Al-Kali A, Hogan W J and Elliott M A. 20180829. Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis. : Blood cancer journal.

Harvard

Haddox C. L., Mangaonkar A. A., Chen D., Shi M., He R., Oliveira J. L., Litzow M. R., Al-Kali A., Hogan W. J. and Elliott M. A. (20180829). Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis. : Blood cancer journal.

MLA

Haddox C L, Mangaonkar A A, Chen D, Shi M, He R, Oliveira J L, Litzow M R, Al-Kali A, Hogan W J and Elliott M A. Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis. : Blood cancer journal. 20180829.